Compounding Pharmacies
6 articles on Compounding Pharmacies, written by Shotlee and medically reviewed for clinical accuracy.
Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
4 min read
Wellness Awaits RFK Jr.'s FDA Move on Peptides
Health Secretary RFK Jr. hinted at FDA easing restrictions on popular peptides like BPC-157 and ipamorelin during a Joe Rogan podcast. Wellness fans hope for access from ethical suppliers, but experts warn of black market dangers. Discover the regulatory shift's potential impact on peptide therapy.
5 min read
Peptide Gold Rush: Deregulation Set to Supercharge Shadow Industry
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
5 min read
RFK Jr. Plans to Unban 14 FDA-Banned Peptides, Tells Joe Rogan
RFK Jr. revealed on the Joe Rogan Experience his intent to lift FDA restrictions on 14 banned peptides from compounding pharmacies. This reversal addresses the late 2023 Category 2 list ban amid safety concerns and black market shifts. Patients and wellness advocates await formal decisions in coming weeks.
5 min read
Semaglutide: Artificial Shortage as Novo Nordisk's Business Model?
Novo Nordisk's lawsuit against Hims & Hers claims compounded semaglutide sales are illegal now that shortages ended. But is this about patient safety or enforcing high prices like $150/month for Wegovy pills versus $50 alternatives? Dive into how patents create artificial semaglutide shortages.
5 min read
The GLP-1 Transformation: Aesthetic Medicine And The Impending Struggle For Dominance
GLP-1 medications have evolved beyond endocrinology to influence medical aesthetics, creating a hybrid market where pharmaceuticals meet consumer identity. This shift highlights opportunities in MedSpas and compounding pharmacies but also poses significant risks. Manufacturers must adapt to maintain control in this evolving landscape.
5 min read